Beam Therapeutics Inc. (BEAM)
Health Care ยท Biological Products, (No Diagnostic Substances)
Beam Therapeutics Inc. (BEAM) is listed on Nasdaq, where its shares have traded since February 6, 2020. SentiSense covers Beam Therapeutics Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). John Evans is its chief executive officer. The company reports 540 employees, and its corporate website is www.beamtx.com.
About Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Latest reported results
Beam Therapeutics Inc. reported revenue of $307.0 thousand for Q3 FY2026, down 96.8% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 270 institutions reported holding BEAM, with 109.4 million shares worth $3.8 billion in aggregate. The largest reported holders were FMR, Vanguard and Farallon Capital Management.
More on BEAM
- BEAM sentiment: whether news and social coverage of Beam Therapeutics Inc. leans bullish or bearish, and the stories driving it.
- BEAM ownership: all 270 reporting institutions, plus insider and congressional trades.
- BEAM financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
Frequently asked questions
What does Beam Therapeutics Inc. do?
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases.
What sector is BEAM in?
SentiSense classifies Beam Therapeutics Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does BEAM stock trade?
Beam Therapeutics Inc. (BEAM) is listed on Nasdaq, where its shares have traded since February 6, 2020.
Who is the CEO of Beam Therapeutics Inc.?
John Evans is the chief executive officer of Beam Therapeutics Inc..